IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
Open Access
- 15 April 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 634
Abstract
Despite the great impact on long-term survival of some cancer patients, the immune checkpoint blockade (ICB) therapy is limited by its low response rates for most cancers. There is a pressing need for novel combination immunotherapies that overcome the resistance to current ICB therapies. Cytokines play a pivotal role in tumor immunotherapy by helping initiating and driving antitumor immune responses. Here, we demonstrated that, besides conventional CD4+ and CD8+ T cells, IL36 surprisingly increased the number of tumor-infiltrating regulatory T (Treg) cells in vivo and enhanced proliferation of Tregs in vitro. Administration of CTLA-4 monoclonal antibodies (mAbs) strongly enhanced IL36-stimulated antitumor activities through depletion of Tregs. In addition, a cancer gene therapy using the IL36-loaded nanoparticles in combination with CTLA-4 mAbs synergistically reduced lung metastasis of breast tumor cells. We further showed that the combined therapy of CTLA-4 mAbs and IL36 led to an increase in proliferation and IFN-γ production by CD4+ and CD8+ T cells when compared to single therapy with CTLA-4 mAbs or IL36. Collectively, our findings demonstrated a new combination therapy that could improve the clinical response to ICB immunotherapy for cancer.Keywords
Funding Information
- Foundation for the National Institutes of Health (R21CA205727)
This publication has 51 references indexed in Scilit:
- Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAsScience Translational Medicine, 2019
- Cytokines in clinical cancer immunotherapyBritish Journal of Cancer, 2018
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- IL-36γ signaling controls the induced regulatory T cell–Th9 cell balance via NFκB activation and STAT transcription factorsMucosal Immunology, 2017
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanomaJournal of Experimental Medicine, 2013
- Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalkJournal of Clinical Investigation, 2012
- The Double-Stranded RNA Analogue Polyinosinic-Polycytidylic Acid Induces Keratinocyte Pyroptosis and Release of IL-36γJournal of Investigative Dermatology, 2012
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994